GSK2256294A (5-30 mg/kg; p.o. twice daily 5 days/week for two weeks) inhibits the generation and maintenance of pulmonary inflammation in cigarette smoke-exposed mice[1].
GSK2256294A (30 mg/kg; p.o. twice daily for 8 days) decreases pulmonary inflammation in cigarette smoke-exposed mice[1].
| Animal Model: | Mice exposed to cigarette smoke 5 days/week for 2 weeks[1] |
| Dosage: | 5 and 30 mg/kg |
| Administration: | Oral gavage; 5 and 30 mg/kg twice daily 5 days/week; for 2 weeks |
| Result: | Dose-dependently inhibited numbers of BAL fluid total cells, neutrophils, macrophages and the keratinocyte chemoattractant (KC) levels in lung tissue. |
| Animal Model: | Mice exposed to cigarette smoke 5 days/week for 2 weeks[1] |
| Dosage: | 30 mg/kg |
| Administration: | Oral gavage; 30 mg/kg twice daily; for 8 days |
| Result: | Significantly reduced neutrophils, macrophages and pulmonary inflammation in cigarette smoke-exposed mice. |
